PGN-EDO51
PepGen's investigational peptide-PMO conjugate for Duchenne muscular dystrophy exon 51 skipping — discontinued in 2024 after Phase 1 results showed lower-than-expected exon skipping efficiency.
What is PGN-EDO51?
PGN-EDO51 was PepGen's investigational peptide-phosphorodiamidate morpholino oligomer (PMO) conjugate designed to induce exon 51 skipping in dystrophin pre-mRNA for the treatment of Duchenne muscular dystrophy (DMD) patients with exon 51-amenable mutations (approximately 13% of DMD patients). The molecule combined PepGen's Enhanced Delivery Oligonucleotide (EDO) peptide platform — a cell-penetrating peptide designed to improve oligonucleotide delivery to skeletal and cardiac muscle — with a PMO targeting the dystrophin exon 51 splice junction, similar in target and mechanism to eteplirsen (Exondys 51, FDA-approved 2016). The program was **discontinued by PepGen in 2024** after Phase 1 dose-escalation results showed lower-than-expected exon skipping efficiency, reframing the EDO platform's near-term applicability. The entry remains in this catalog for completeness — the program illustrates the persistent challenge of muscle-targeted oligonucleotide delivery in DMD.
What PGN-EDO51 Is Investigated For
PGN-EDO51 was PepGen's lead Phase 1 program for DMD exon 51 skipping, designed to compete with eteplirsen (Exondys 51) using a cell-penetrating peptide-conjugated PMO. The 2024 Phase 1 results showed exon skipping efficiency below pre-specified thresholds, leading PepGen to discontinue the program in late 2024. The HFCRD-DM1 / PGN-EDODM1 program for myotonic dystrophy type 1 was also discontinued. PepGen has pivoted its development focus following these decisions. For DMD patients, the available approved exon-skipping therapies (eteplirsen for exon 51, golodirsen for exon 53, viltolarsen for exon 53, casimersen for exon 45) remain the established options, with subsequent peptide-mediated approaches (Vertex's VX-670 for DM1, Avidity's del-zota for DM1, others) at varying development stages.
History & Discovery
PepGen was founded around the EDO cell-penetrating peptide platform for improving oligonucleotide delivery to skeletal and cardiac muscle. PGN-EDO51 was the lead DMD candidate, and PGN-EDODM1 was the parallel myotonic dystrophy candidate. The Phase 1 dose-escalation trials in 2023–2024 produced exon skipping or DMPK reduction levels below the prespecified thresholds, and PepGen discontinued both programs in late 2024. The company has since pivoted strategically. The DMD oligonucleotide delivery problem remains unsolved at the clinical efficiency level needed for substantial dystrophin restoration. Multiple subsequent peptide-conjugate approaches (Avidity, Sarepta peptide-PMOs, others) are at varying development stages, and Vertex's VX-670 for DM1 entered Phase 1 in 2024–2025. The PepGen discontinuation underscores the technical difficulty of the muscle oligonucleotide delivery problem.
How It Works
DMD is caused by mutations in the dystrophin gene that prevent muscle cells from producing functional dystrophin protein. Exon skipping therapies use oligonucleotides to make muscle cells skip over the mutated exon during RNA processing, producing a shorter but still functional dystrophin protein. PGN-EDO51 was designed to do this for the exon 51 mutation, using a cell-penetrating peptide to deliver the oligonucleotide into muscle cells more efficiently. The approach didn't achieve enough exon skipping in Phase 1 to continue development.
PGN-EDO51 consisted of a phosphorodiamidate morpholino oligomer (PMO) targeting the dystrophin exon 51 splice junction, conjugated to PepGen's EDO cell-penetrating peptide platform. The PMO portion was mechanistically similar to eteplirsen — designed to hybridize with the splice signal at exon 51 and force exon 51 skipping during pre-mRNA processing, producing a truncated but partially functional dystrophin protein in patients with exon 51-amenable mutations. The EDO peptide was intended to improve cellular uptake of the PMO in skeletal and cardiac muscle, addressing the major limitation of naked PMO therapy (low muscle uptake). The Phase 1 readout in 2024 measured dystrophin restoration and exon skipping efficiency in muscle biopsy. The results were below the pre-specified threshold for continued development, leading to program discontinuation.
Evidence Snapshot
Human Clinical Evidence
Phase 1 complete with discontinuation in 2024.
Animal / Preclinical
Adequate. EDO platform demonstrated muscle delivery improvement in preclinical models.
Mechanistic Rationale
Strong. Exon 51 skipping is mechanistically validated by eteplirsen approval; the delivery platform was the differentiator.
Research Gaps & Open Questions
What the current literature has not yet settled about PGN-EDO51:
- 01Why peptide-PMO conjugates have not achieved the dystrophin restoration thresholds needed for clinical benefit in DMD — a technical question relevant to ongoing peptide-oligonucleotide programs.
- 02Whether the EDO platform can be optimized for other oligonucleotide targets or whether the fundamental approach faces a ceiling.
Forms & Administration
Was IV infusion in Phase 1 trials. Not commercially available — program discontinued.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Was Phase 1 dose-escalation; program discontinued.
Frequency
N/A — program discontinued.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
N/A.
Protocol Notes
PGN-EDO51 is not in active development. DMD patients with exon 51 mutations have eteplirsen (Exondys 51) as an FDA-approved option, with the recognition that eteplirsen's clinical efficacy has been debated and exon-skipping levels are modest.
Program discontinued; not available.
Timeline of Effects
Onset
Not relevant — discontinued.
Peak Effect
Not relevant.
After Discontinuation
Not relevant.
Common Questions
Who PGN-EDO51 Is NOT For
- •Program discontinued — no clinical indication.
Drug & Supplement Interactions
Not characterized. Program discontinued.
Safety Profile
Common Side Effects
Cautions
- • Program discontinued in 2024 — no clinical path forward
What We Don't Know
No further development planned.
Legal Status
United States
Program discontinued in 2024. Not FDA-approved and no further regulatory path.
International
Same — discontinued globally.
Sports & Competition
Not relevant.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Peptide-PMO conjugates are a solved technology for DMD.
Reality
PGN-EDO51's discontinuation in 2024 demonstrates that the delivery problem remains technically difficult. Subsequent peptide-conjugate approaches must achieve materially better exon skipping efficiency to justify clinical development.
Quick Facts
- Class
- Cell-Penetrating Peptide-PMO Conjugate
- Tier
- F
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- May 2026
- Citations
- 0PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.